iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference

Rhea-AI Summary

iBio (NASDAQ: IBIO) announced it will participate in the Wells Fargo 21st Annual Healthcare Conference in Boston, held September 8–10, 2026. CEO and Chief Scientific Officer Martin Brenner will join a fireside chat on September 8 at 4:30 p.m. ET, available via livestream and 90-day webcast replay on iBio’s Investor Relations site.

CFO Felipe Duran will join Dr. Brenner for one-on-one investor meetings during the conference, which can be requested by contacting the company’s investor relations email. iBio is a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, cancer, and other hard-to-treat conditions.

Market Context

IBIO's prior conference announcement recorded a 4.55% 24-hour reaction, while its Phase 1 dosing ann...

Analysis

IBIO's prior conference announcement recorded a 4.55% 24-hour reaction, while its Phase 1 dosing announcement recorded -6.88%. The active S-3 shelf and absent recent insider activity add context to this scheduling event.

Key Figures

Conference edition: 21st annual Conference dates: September 8-10, 2026 Fireside chat time: 4:30 p.m. ET +1 more

4 metrics

Conference edition 21st annual Wells Fargo Healthcare Conference

Conference dates September 8-10, 2026 Boston

Fireside chat time 4:30 p.m. ET Tuesday, September 8, 2026

Replay availability 90 days Investor Relations webcast replay

Historical Context

5 past events · Latest: Aug 28 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 28	Fiscal year results	Negative	-2.5%	Lower revenue and wider net loss accompanied the fiscal-year corporate update.
Aug 04	Leadership appointment	Positive	+2.8%	Molly Carr joined as chief medical officer with clinical and biopharma experience.
Jul 01	Preclinical data	Positive	+0.0%	IBIO-610 produced sustained Activin E inhibition and improved fat-loss measures.
Jun 02	Investor conferences	Neutral	+4.5%	The company announced participation in two healthcare investor conferences.
Jun 02	Phase 1 initiation	Positive	-6.9%	The first participant was dosed in the IBIO-600 obesity clinical trial.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Historical reactions were mixed, ranging from -6.88% to +4.55%, with clinical-stage updates showing the widest divergence from positive announcement sentiment.

Key Terms

cardiometabolic, cardiopulmonary, antibody therapeutics

3 terms

cardiometabolic medical

"developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases"

Cardiometabolic describes health conditions that affect the heart and the body’s metabolism—most commonly heart disease, high blood pressure, type 2 diabetes and obesity—that often occur together and share common causes. Investors care because these linked conditions drive large, predictable demand for drugs, medical devices and long-term care, and changes in treatment options, guidelines or costs can materially affect healthcare company revenues and government spending much like a problem in an engine and its fuel system impacts the whole vehicle.

cardiopulmonary medical

"long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases"

Relating to the combined function of the heart and lungs—how the heart pumps blood and the lungs oxygenate that blood and remove waste gases. Investors watch cardiopulmonary issues because treatments, devices, or clinical results in this area can affect demand, regulatory reviews, hospital spending and patient outcomes; think of the heart and lungs as a vehicle’s engine and fuel system—if either falters, the market for repairs and improvements can change quickly.

antibody therapeutics medical

"developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases"

Antibody therapeutics are medicines made from proteins the immune system uses, engineered to stick to specific molecules or cells to block disease or mark them for removal. They matter to investors because successful antibody drugs can command high prices and large markets, but their value hinges on clinical trial outcomes, manufacturing complexity, regulatory approval and patent protection—like custom-made keys that can open big rewards or be hard to replicate.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced that it will participate in the Wells Fargo 21st Annual Healthcare Conference, taking place September 8-10, 2026, in Boston.

Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer of iBio, will participate in a fireside chat on Tuesday, September 8, at 4:30 p.m. ET.

A livestream of the event can be accessed here, and a replay of the presentation webcast will be available on the Investor Relations section of the iBio website for 90 days following the event.

Felipe Duran, iBio’s Chief Financial Officer, will be available with Dr. Brenner for one-on-one investor meetings during the conference. To request a meeting with Dr. Brenner or Mr. Duran at either conference, please contact ir@ibioinc.com.

About iBio, Inc.

iBio (Nasdaq: IBIO) is a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, cancer, and other hard-to-treat diseases. Combining advanced antibody engineering with AI-driven discovery, iBio is advancing a differentiated pipeline designed to deliver sustained therapeutic effects and address significant unmet medical needs. iBio’s mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine.

For more information, visit www.ibioinc.com or follow us on LinkedIn.

Contact:

iBio, Inc.
Investor Relations
ir@ibioinc.com

Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310 or (646) 942-5604

FAQ

When will iBio (NASDAQ: IBIO) present at the 2026 Wells Fargo Healthcare Conference?

iBio will participate in a fireside chat on September 8, 2026, at 4:30 p.m. ET. According to iBio, this session is part of the Wells Fargo 21st Annual Healthcare Conference held September 8–10, 2026, in Boston.

How can investors watch iBio’s webcast from the 2026 Wells Fargo Healthcare Conference?

Investors can watch a livestream of iBio’s fireside chat via a provided online link. According to iBio, a replay of the presentation webcast will be available on the company’s Investor Relations website for 90 days following the event.

Will iBio management be available for one-on-one investor meetings at the 2026 Wells Fargo Healthcare Conference?

Yes, iBio’s CEO Martin Brenner and CFO Felipe Duran will be available for one-on-one investor meetings. According to iBio, investors can request meetings by contacting the company at ir@ibioinc.com during the conference dates.

What is iBio’s business focus as highlighted in its September 2026 conference announcement?

iBio is a clinical-stage biotechnology company developing long-acting antibody therapeutics. According to iBio, its programs target obesity, cardiometabolic and cardiopulmonary diseases, cancer, and other hard-to-treat conditions, using advanced antibody engineering and AI-driven discovery to build a differentiated pipeline.

Where can investors find more information about iBio (IBIO) around the 2026 Wells Fargo conference?

Investors can learn more about iBio by visiting www.ibioinc.com and its Investor Relations section. According to iBio, additional updates, including the conference webcast replay, and company information are also accessible via its LinkedIn presence and investor relations contacts.